Scarsdale, NY, United States of America

Manish Sharma

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Manish Sharma: Innovator in Cancer Treatment

Introduction

Manish Sharma is a notable inventor based in Scarsdale, NY (US). He has made significant contributions to the field of cancer treatment, particularly in the area of multiple myeloma. His innovative work has led to the development of a unique therapeutic approach that utilizes bispecific antibodies.

Latest Patents

Manish Sharma holds a patent for "Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies." This invention focuses on the use of bispecific antibodies that bind to both B-cell maturation antigen (BCMA) and CD3. The method aims to activate T cells in the presence of BCMA-expressing tumor cells, providing a promising avenue for treating multiple myeloma. The bispecific antigen-binding molecules developed in this patent are capable of inhibiting the growth of tumors that express BCMA. He has 1 patent to his name.

Career Highlights

Manish Sharma is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to advance his research in cancer therapies. His work at Regeneron has positioned him as a key player in the pharmaceutical industry, contributing to innovative solutions for complex medical challenges.

Collaborations

Some of his notable coworkers include Israel Lowy and David Sternberg. Their collaborative efforts have further enhanced the research and development of effective treatments for cancer.

Conclusion

Manish Sharma's contributions to the field of cancer treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work at Regeneron Pharmaceuticals, Inc. continues to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…